Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Revised Redemption Agreement with Global Pharm

21 Oct 2015 08:49

RNS Number : 9379C
Adamas Finance Asia Limited
21 October 2015
 

Adamas Finance Asia Limited

(the "Company")

 

REVISED REDEMPTION AGREEMENT WITH Global Pharm

 

 

Further to the announcement made on 20 August 2015, the Company announces that through its 75% owned subsidiary, Blazer Delight Limited ("Blazer Delight"), it has entered into a revised agreement for the redemption of the remainder of the convertible bond held in the Chinese pharmaceutical company, Global Pharm Holdings Group Inc. ("Global Pharm") (the "Revised Agreement").

 

Through the previous redemption agreement announced on 18 December 2014, the Company was due to receive an initial payment of US$2.4 million on 31 December 2014, a further US$9 million on 31 March 2015 and a final payment of US$13.6 million on 30 April 2015, an aggregate of US$25 million. The initial payment was received, but the second and third payments were not made in accordance with the agreement. However, Global Pharm has since made further payments to Blazer Delight, which total US$5.44 million, net to the Company.

 

Under the Revised Agreement, Global Pharm has agreed to make payments to Blazer Delight of not less than US$750,000 per month, net to the Company. All amounts received under the Revised Agreement will be offset against the two payments which were due on 31 March 2015 and 30 April 2015 and which remain subject to penalty interest of 26% per annum, compounded on a daily basis. 

 

Subject to certain limited exclusions, Global Pharm Holdings Limited, LLC, a major shareholder in Global Pharm, has undertaken to transfer shares in Global Pharm to Blazer Delight in respect of any monthly payments that are not made on time and in full. For each monthly payment not made on time and in full, shares equivalent to 0.00375%, net to the Company, of the issued and outstanding share capital of Global Pharm, will be transferred on the first business day of each year commencing in 2016, subject to a maximum of 0.075%, net to the Company.

 

 

 

Enquiries:

 

Adamas Finance Asia Limited

John Croft

 

+44 (0) 1825 830587

Nominated Adviser

W H Ireland Limited

Tim Feather

Liam Gribben

+44 (0) 113 394 6600

Broker

Edmond de Rothschild Securities (UK) Limited

 

+44 (0) 20 7845 5950

John Armstrong-Denby

Hiroshi Funaki

Public Relations Advisers

Ryan Communication (Hong Kong)

Scott McFarlane

 

+852 6297 3801

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRDFLBLEBFZFBZ
Date   Source Headline
5th Dec 20169:00 amRNSDirector/PDMR Shareholding
28th Nov 201610:00 amRNSDirector/PDMR Shareholding
23rd Nov 20169:11 amRNSDirector/PDMR Shareholding
31st Oct 20168:05 amRNSDirector/PDMR Shareholding
24th Oct 20162:48 pmRNSDirector/PDMR Shareholding
17th Oct 201612:30 pmRNSDirector/PDMR Shareholding
12th Oct 20168:35 amRNSDirector/PDMR Shareholding
7th Oct 20168:45 amRNSre: redemption of Global Pharm Convertible Bond
6th Oct 20169:26 amRNSRestructuring of Investment in Fortel
29th Sep 20169:31 amRNSDirector/PDMR Shareholding
26th Sep 20167:00 amRNSReceipt of US$820,000 from GCCF
23rd Sep 20162:40 pmRNSDirector/PDMR Shareholding
16th Sep 201610:13 amRNSDirector/PDMR Shareholding
12th Sep 20168:54 amRNSHalf Yearly Report
1st Sep 20167:00 amRNSChange of Adviser
28th Jul 20164:40 pmRNSSecond Price Monitoring Extn
28th Jul 20164:35 pmRNSPrice Monitoring Extension
21st Jul 201610:26 amRNSResult of AGM
6th Jul 20167:00 amRNSGCCF successfully exits Project Media
28th Jun 20168:37 amRNSRepayment of Loan by Portfolio Company
23rd Jun 20168:22 amRNSFinal Results
6th Apr 201610:36 amRNSRealisation of Investment in BRJ
1st Apr 201611:23 amRNSGlobal Pharm Update
31st Mar 20167:00 amRNSChange of Adviser
1st Mar 20169:37 amRNSDealing by Mark Hibbs
27th Jan 20168:01 amRNSGlobal Pharm Update
15th Jan 20169:34 amRNSDirector/PDMR Shareholding
7th Jan 20163:07 pmRNSUpdate on proposed IPO of HKMH
22nd Dec 201510:56 amRNSBroker Update
4th Dec 20157:00 amRNSAdamas AM & Ping An Trust Joint Venture Fund
30th Nov 20152:30 pmRNSGlobal Pharm Update
17th Nov 201512:04 pmRNSHolding(s) in Company
26th Oct 201510:56 amRNSRevised Redemption Agreement with Global Pharm
21st Oct 20158:49 amRNSRevised Redemption Agreement with Global Pharm
5th Oct 20157:00 amRNSADAM to invest a further $3m in Adamas' GCCF
18th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSAdamas Strengthens its Executive Team
20th Aug 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
20th Jul 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
3rd Jul 20157:00 amRNSA1 Filing by HKMH
19th Jun 20157:00 amRNSFinal Results
15th Jun 201512:35 pmRNSUpdate on Disposal of Interest in Global Pharm
15th May 201512:09 pmRNSUpdate on Disposal of Interest in Global Pharm
29th Apr 20157:00 amRNSBroker Update
9th Apr 20158:37 amRNSAppointment of Broker
8th Apr 201510:53 amRNSResult of General Meeting
7th Apr 20154:40 pmRNSSecond Price Monitoring Extn
7th Apr 20154:35 pmRNSPrice Monitoring Extension
1st Apr 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
20th Mar 20153:11 pmRNSChange of Investing Policy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.